Opinion
Video
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL